biopharma

Trend: Biopharma embraces digital cognitive assessments to identify behavioral health biomarkers

by

_______

The hunt for behav­ioral health bio­mark­ers is har­ness­ing dig­i­tal health at the research stage (Med­C­i­ty News):

“Dig­i­tal health com­pa­nies are going through an inter­est­ing trans­for­ma­tion as research insti­tu­tions real­ize the ben­e­fit of their tech­nol­o­gy to col­lect and man­age data for a host of stud­ies. The bio­phar­ma industry’s embrace of some dig­i­tal health tools to man­age the costs of drug devel­op­ment has led to more fre­quent col­lab­o­ra­tions with [Read more…] about Trend: Bio­phar­ma embraces dig­i­tal cog­ni­tive assess­ments to iden­ti­fy behav­ioral health biomarkers

Akili raises an additional $11.9M; brings Amgen, Merck, Pfizer and Shire to the digital medicine table

by

akili-game—–

Akili Adds Amgen Ven­tures and M Ven­tures* to Series B Financ­ing, Increas­ing Round to $42.4 Mil­lion (press release):

“Akili Inter­ac­tive Labs, Inc. (“Akili”), a dig­i­tal med­i­cine com­pa­ny devel­op­ing nov­el, non-phar­ma­co­log­i­cal ther­a­peu­tics and diag­nos­tics for cog­ni­tive dis­or­ders, today announced an $11.9 mil­lion expan­sion of its recent Series B financ­ing. [Read more…] about Akili rais­es an addi­tion­al $11.9M; brings Amgen, Mer­ck, Pfiz­er and Shire to the dig­i­tal med­i­cine table